Clinical trial · Observational
Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Erythropoietin, EPO, is the main regulator and stimulator of bone marrow erythropoiesis, and is responsible for growth and differentiation of the erythroid cell lineage. Our team, in collaboration with partners (see below) has taken responsibility to study the presence, function and clinical significance of EPO-R in human cancer specimens. General Aim of the Proposed Project: To study EPO-R in human cancer specimens. Prepared slides from already taken preparations (specimens from Bone Marrow tests) will serve as the basis for that part of the work.Specimens will be taken from Breast cancer, Colon cancer, Lung cancer, Head \& Neck cancer and from Lymph nodes biopsy (positive for lymphoma) The slides will be stained with anti-EPO-R antibodies (Abs).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- People with diagnosed cancer
- description
- People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
Primary outcomes (1)
- measure
- anti-EPO-R antibodies staining
- timeFrame
- 1 year
- description
- The specimens from Biopsy/Bone Marrow test will be collected once immediately after ICF signing in prospective part. In retrospective part, the specimens will be taken once from the same donor.
Secondary outcomes (1)
- measure
- Follow up after prospective participants
- timeFrame
- 3 years
- description
- o Patients will be identified, with a 2-3 year follow-up on the clinical course and an attempt to correlate the course and clinical outcome with the presence and function of the EPO-R on the tumor cells.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (more than 17 years old) * With one of next cancer types: breast, lung, colon, head, neck and lymphoma * I prospective part only: that signed ICF Exclusion Criteria: * Teenagers below 18 years old * In prospective part: that did not sign ICF
References
Publications (5)
- BACKGROUNDLin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7580-4. doi: 10.1073/pnas.82.22.7580. PMID 3865178
- BACKGROUNDEschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989 Jul 20;321(3):158-63. doi: 10.1056/NEJM198907203210305. PMID 2747747
- BACKGROUNDSpivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994 Aug 15;84(4):997-1004. No abstract available. PMID 8049455
- BACKGROUNDBokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19. PMID 17182241
- BACKGROUNDRizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 1;111(1):25-41. doi: 10.1182/blood-2007-08-109488. Epub 2007 Oct 22. PMID 17954703